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Abstract
Objectives The objective of the present study was to investigate the effect of lipoxin-type A4 (LXA4) on bacterial-induced
osteoclastogenesis.
Material and methods Human periodontal ligament cells (PDLCs) in coculture with osteoclast precursors (RAW264.7 cells)
were exposed to bacterial stimulation with lipopolysaccharide (LPS) to induce inflammation. After 24 h, cells were treated to 100
ng/ml of LXA4 and 50 ng/ml of forymul peptide receptor 2 (FPR2/ALX) receptor antagonist (Boc-2). After 5 days, osteoclastic
resorptive activity was assessed on calcium phosphate (CaP) synthetic bone substitute. Additionally, osteoclastic differentiation
was evaluated using tartrate-resistant acid phosphatase (TRAP) staining, TRAP enzymatic activity assay, and on the expression
of osteoclast-specific genes.
Results We found that stimulation of in the osteoclasts with LPS-stimulated PDLCs induced a significant increase in tartrate-
resistant acid phosphatase (TRAP) positive cells, higher resorptive activity, and enhanced expression of specific genes.
Meanwhile, LXA4-treatment exhibited strong anti-inflammatory activity, and was able to reverse these inflammatory effects.
Conclusions We conclude that (1) PDLCs are a potential target for treating bacterial-induced bone resorption in patients with
periodontal disease, and (2) LXA4 is a suitable candidate for such therapy.
Clinical relevance The results prove that lipoxins have a protective role in bacterial-induced periodontal inflammation and
alveolar bone resorption, which can be translated into a clinical beneficial alterative treatment.
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Introduction
Periodontal disease, the most common chronic disease in
humans, is characterized by inflammation of the supporting
tissues around the teeth [1]. Alveolar bone loss is one of the
major hallmarks for disease progression, and combatting bone
loss is therefore key to treating periodontal disease [2].
Normal bone remodeling is a dynamic process maintained
by a balance between bone formation and resorption [3, 4].
In periodontal disease, chronic inflammation disrupts the ho-
meostatic balance between bone formation and bone resorp-
tion, in favor of bone loss [5]. There is evidence that the
periodontal ligament (PDL) plays an important role in the
remodeling of alveolar bone [5].
Periodontal ligament cells (PDLCs) are specialized
spindle-shaped cells responsible for maintaining the integrity
of the ligament that is connecting the tooth root cementum to
the alveolar jaw bone [6]. However, in chronic inflammation
(i.e., periodontitis), the phenotype of PDLCs changes, leading
to a tissue-destructive response [7]. Microorganisms (e.g.,
Porphyromonas gingivalis, Fusobacterium nucleatum, and
Escherichia coli) promote the PDLCs to interact with osteo-
clast progenitor cells (OPCs), which leads to the differentia-
tion of these OPCs into mature osteoclasts [8, 9]. During this
interaction, PDLCs attract and stimulate the differentiation of
OPCs towards mature osteoclasts via expression of adhesion
molecules, such as adhesion molecule-1 (ICAM-1), and ex-
pression of osteoclastogenesis stimulatory factors, such as
RANKL, M-CSF, and tumor necrosis factor-alpha (TNFα)
[10]. In vivo, this leads to retraction of PDLCs and migration
of OPCs to the bone surface; where the OPCs mature into
bone-resorbing osteoclasts [11–14]. Consequently, the cas-
cade of infection, inflammation mediated by the PDLCs, and
osteoclast differentiation presents an important drug target for
therapeutic agents aimed at suppressing bone loss.
* X. Frank Walboomers
frank.walboomers@radboudumc.nl
1 Department of Dentistry, Biomaterials, Radboud Institute for
Molecular Life Sciences, Radboud University Medical Center,
Philips van Leydenlaan 25, 6525EX Nijmegen, The Netherlands
https://doi.org/10.1007/s00784-020-03385-3
/ Published online: 6 June 2020
Clinical Oral Investigations (2021) 25:957–969
Over the last decade, there has been an increasing number
of studies on the anti-inflammatory effect of specialized pro-
resolving mediators (SPMs), and especially of lipoxins (LXs)
[15, 16]. More recently, other effects of LXs have been ob-
served, including the role of LXs in preventing bone resorp-
tion [17]. LXs are endogenous metabolic products derived
from arachidonic acid metabolism, which have important
pro-resolving and anti-inflammatory properties [18–20].
Lipoxin-type A4 (LXA4) binds specifically to a G protein-
coupled N-formyl peptide receptor 2 (FPR2/ALXR)
expressed by a variety of inflammatory cells, and which is
also expressed in PDLCs [21]. The binding of LXA4 to its
receptor induces a pro-resolving effect mainly by suppressing
the expression of inflammatory mediators (e.g., IL-1β and IL-
6) via inhibition of multiple signaling pathways, including
receptor activator of nuclear factor-κB (NF-κB), which op-
poses inflammation [17, 22, 23]. The anti-inflammatory effect
of LXA4 is well documented in the literature [22, 24].
However, the effect of LXA4 on bacterial-induced osteoclas-
tic differentiation during cell-cell contact between PDLCs and
OPCs remains elusive.
Given the relationship between inflammation and osteo-
clast formation and function, we hypothesized that (1)
LXA4 would have an inhibitory effect on bacterial-induced
osteoclastogenesis, and (2) this effect would be reversed by
FPR2/ALXR antagonist, Boc-2. To test this hypothesis, we
developed a coculture model derived from a murine
RAW264.7 osteoclast cell line, in direct contact with primary
human PDLCs in vitro. After induction of an inflammatory
phenotype of the PDLC (by the addition of E. coli lipopoly-
saccharide; LPS), the osteoclastic differentiation was evaluat-
ed by means of TRAP staining, TRAP enzymatic activity
assay, resorption of a calcium phosphate substrate, and ex-
pression levels of osteoclast-specific genes.
Material and methods
Reagents and chemicals
Synthetic LXA4was purchased fromCayman Chemical (Ann
Arbor, MI, USA), and Boc-Phe-Leu-Phe-Leu-Phe (Boc-2)
was purchased from Phoenix Pharmaceutical (Burlingame,
CA, USA). Dulbecco’s Modified Eagle’s Medium
(DMEM/F-12), Minimum Essential Medium Eagle alpha
(αMEM), sterile phosphate buffered saline (PBS), fetal bo-
vine serum (FBS), penicillin-streptomycin (PS), and trypsin-
EDTA solution were all purchased from Gibco (Delft,
Netherlands). Phosphate buffered saline (PBS) tablets and
Acid Phosphatase Leukocyte Staining Kit (387A) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA).
Commercially available preparations of LPS from E. Coli
were purchased from InvivoGen (San Diego, CA, USA).
Murine activator of nuclear factor-κ B ligand (mRANKL)
was purchased from Peprotech (Rocky Hill, NJ, USA). All
cell culture flasks and plates were purchased from Greiner
Bio-one (Frickenhausen, Germany). The RNA Isolation Kit
was obtained from Qiagen (Venlo, Netherlands). TaqMan
Reverse Transcription kit and Fast SYBR Green Master Mix
Kit were obtained from Thermo Fisher Scientific (Breda,
Netherlands).
Calcium phosphate coating
Abiomimetic calcium phosphate (CaP) coating was applied to
glass coverslips using a two-stage process as described else-
where [25, 26]. The first stage involved immersing the glass
slides in a 2.5-fold simulated body fluid (SBF) solution (1 ml/
well) at room temperature under light agitation for 3 days and
daily refreshment of the solution. A total of 2.5-fold SBF was
prepared by mixing Tris buffer (0.05 M; pH adjusted to 7.4
using 1MHCl), calcium stock solution, and a phosphate stock
solution together in a ratio of 2:1:1. The calcium and phos-
phate stock solution was prepared by dissolving the reagents
specified in Table 1 in Tris buffer solution. The second stage
involved immersing the glass coverslips in a calcium phos-
phate solution (CPS) (1 ml/well) for 1 day at room tempera-
ture under light agitation. CPS was prepared by fully dissolv-
ing each reagent in the order listed in Table 1 in MilliQ water,
while ensuring that the pH did not rise above 8 using 1MHCl.
Once all the Tris was fully dissolved, the pH was adjusted to
7.4. After 1 day of soaking, the CPS was aspirated from the
wells and 70% ethanol was added and left to evaporate to
sterilize the CaP-coated glass coverslips. Lastly, the coverslips
were gently rinsed three times with MilliQ water and dried
overnight at room temperature before use in cell culture. Prior
to cell seeding, the CaP-coated glass coverslips were incubat-
ed in FBS for 1 h at 37 °C.
Table 1 Reagents used to prepare calcium and phosphate stock
solutions, as well as CPS. Reagents for the calcium and phosphate
stock solutions were dissolved using a 0.05 M Tris buffer solution with
a pH adjusted to 7.4 using 1 M HCl, while reagents for the CPS were
dissolved in MilliQ water
Solution Reagent formula Molar mass Molarity (M)
Calcium stock CaCl2 ● 2H2O 147.02 0.025
NaCl 58.44 1.37
MgCl2 ● 6H2O 203.30 0.015
Phosphate stock NaH2PO4 ● 2H2O 156.01 0.0111
NaHCO3 84.01 0.042
CPS NaH2PO4 ● 2H2O 156.01 0.00225
CaCl2 ● 2H2O 147.02 0.004
NaCl 58.44 0.14
Tris 121.1356 0.05
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Coating characterization
SEM To evaluate the morphology of CaP-coated glass cover-
slips with 12-mm diameter (VWR B.V., Amsterdam,
The Netherlands), specimens were sputter-coated with a 30-
nm thin chromium layer and imaged using a scanning electron
microscope (SEM; Zeiss Sigma 300, Zeiss AG, Oberkochen,
Germany).
X-ray diffraction A PANalytical X’Pert3 X-ray diffractometer
(Malvern Panalytical B.V., Eindhoven, The Netherlands) with
a Cu Kα radiation source was employed to perform thin film
X-ray diffraction (XRD) on CaP-coated glass slides using an
incidence grazing angle of 2.5°. The measurements were per-
formed at a voltage and current of 45 kV and 40 mA, respec-
tively, with a step size of 0.02° and a count time of 1 s per step.
All scans were performed between 10° and 50° 2θ.
Fourier transform infrared spectral study spectroscopy
Characterization of the crystal phase of the calcium phosphate
coated on glass slides was investigated using FT-IR spectros-
copy (Spectrum Two FT-IR Spectrometer, PerkinElmer,
Waltham, USA). The samples were scanned in the 4000–
650 cm−1 range with an ATR accessory.
Surface profile Characterization of the surface profile of the
calcium phosphate coated on glass slides was investigated
using Universal Surface Tester (UST®, Innowep GmbH,
Wuerzburg, Germany). The samples were secured to the sam-
ple stage and measurements were taken using the stylus dia-
mond tip (R = 2 μm, 60°) connected to the measurement head
with velocity of 0.1 mm/s bearing the load of 1.0 mN at in-
crements of 2.0 μm for a total distance of 5 mm.
Cell culture
All experiments were done in accordance with the national
guidelines for working with human materials (Dutch
Federation of biomedical scientific societies, human tissue,
and medical research; code of conduct for responsible use.
Available at https://www.federa.org/). The RAW 264.7
murine macrophage cell line (ATCC®TIB-71™) was
purchased from the American Type Culture Collection
(Manassas, VA, USA) and maintained in αMEM medium
supplemented with 10% FBS and 1% PS at 37 °C in a
humidified atmosphere of 5% CO2 until 80% confluence
(number of passages was < 10). After informed patient
consent, human periodontal ligament cells (PDLCs) were har-
vested from several healthy adult donors who underwent ex-
traction of a third molar as previously described [27]. PDLCs
were cultured at 37 °C in a humidified atmosphere of 95% air
and 5% CO2. The medium was replaced every 2 to 3 days
until 50% confluence was reached, and then, the PDLCs were
passaged before being frozen in medium supplemented with
10% dimethyl sulfoxide (DMSO; Sigma-Aldrich). After
defrosting, PDLCs were passaged again and maintained in
sterile 75 cm2 culture flasks with DMEM medium supple-
mented with 10% FBS and 1% PS and cultured at 37 °C in
a humidified atmosphere of 95% air and 5% CO2. For all
experiments, the cell passage was ≤ 5.
RANKL-induced osteoclasts
As a positive test for osteoclast differentiation, RAW264.7
cells were seeded in a 24-well plate (2 × 103 cells/cm3) and
cultured in αMEM supplemented with 10% FBS and 1% PS.
At day 1, medium was refreshed with differentiation medium
(50 ng/ml of murine RANKL) to induce osteoclast formation.
At day 2, medium was refreshed with differentiation medium
supplemented with LXA4 100 ng/ml and Boc-2 50 ng/ml, and
then, cells were returned to the incubator at 37 °C in a humid-
ified atmosphere of 95% air and 5% CO2. The medium was
replaced every 2 days. After 5 days, the cells and medium
were collected for TRAP staining and enzymatic assays.
Parallel samples were collected for mRNA extraction.
LPS/PDLC-induced osteoclasts
Protocol for direct coculture of human PDLCs and murine
RAW264.7 was adapted from a previous protocol [9].
PDLCs were cultured in a 24-well plate (1 × 104 cells/cm3)
with DMEM medium supplemented with 10% FBS and 1%
PS and cultured at 37 °C in a humidified atmosphere of 95%
air and 5% CO2. After 48 h, RAW 264.7 (2 × 10
3 cells/cm3)
were seeded on top of PDLCs using a 1:1 mixture of basic
medium (DMEM:αMEM). After 24 h, cell culture medium
was refreshed with basic medium supplemented with LPS (1
μg/ml) to let PDLCs induce osteoclast formation in
RAW264.7 cells, as shown in Fig. 1. After 24 h, medium
was replenished with fresh medium supplemented with
LXA4 (100 ng/ml) and Boc-2 (50 ng/ml), and cells were cul-
tured accordingly as before. After 5 days, the cells and medi-
um were collected for TRAP staining and enzymatic assays.
Parallel samples were collected for mRNA extraction.
Osteoclast purification and transfer
Purification and transfer of osteoclasts was adapted from
Maria et al. (2014) [26]. After induction of osteoclasts, both
by RANKL and by LPS/PDLC induction, the medium was
aspirated and cells were washed twice with pre-warmed sterile
PBS. To detach undifferentiated cells, 0.25% trypsin (1 ml/
well) was added and the plate was returned to the incubator at
37 °C for 1 min. Themedium containing undifferenced mono-
nucleated cells was aspirated, leaving behind large multinu-
cleated cells (> 100 μm in diameter). The differentiated
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osteoclasts were dislodged from the plate by gently pipetting
the solution, while observing under the microscope. The dif-
ferentiated osteoclasts were then seeded at the exact seeding
density on top of calcium phosphate-coated glass slides that
had been incubated prior with FBS for 1 h at 37 °C. Tissue
culture plates were returned to the incubator carefully and
maintained for 48 h at 37 °C in a humidified atmosphere of
95% air and 5% CO2.
Measurements
Osteoclast resorption
After incubation of osteoclast on CaP-coated glass slides for
48 h, cell culture medium was aspirated, and cells were
washed twice with sterile PBS. The cells were then removed
by incubating with sodium chloride (1 M) in 0.2% Triton-X-
100 for 1–2 min, and subsequently washed withMilliQ water.
To stain for calcium, the CaP-coated glass slides were incu-
bated in silver nitrate solution (5% AgNO3) at RT under an
UV lamp for 1 h. Then, the glass slides were washed with
distilled water and the coating surface was examined by a light
microscope. The osteoclast resorption pits were measured
using Fiji 1.51n software (National Institute of Health,
Bethesda, MD, USA). To study the morphology of osteoclasts
cultured on CaP-coated glass slides, parallel samples contain-
ing cells were fixed with 2.5% glutaraldehyde overnight. After
fixation, cells were dehydrated in a graded ethanol series: 25,
50, 60, 70, 80, 90, 95, 100%—each for 5 min. The cells were
further dehydrated with a graded hexamethyldisilazane
(HMDS; Sigma-Aldrich) series diluted in 100% ethanol: 1:2,
1:1, 2:1 (v/v ratios of HMDS; 100% ethanol). Specimens were
then treated with undiluted 100% HMDS each for 10 min and
allowed to evaporate under the flow hood overnight. Finally,
samples were sputter-coated with gold and imaged according-
ly by SEM.
TRAP staining and TRAP enzymatic activity assay
Tartrate-resistant acid phosphatase (TRAP) enzymatic activity
was measured using the Acid Phosphatase Leukocyte Staining
Kit (Sigma-Aldrich St. Louis, MO) in accordance with the
manufacturer’s instructions. Briefly, 10 ml of acid phospha-
tase staining solution consisting of 9 ml of pre-warmed
MilliQ, 400 μl of acetate solution, 100 μl of naphthol AS-BI
phosphoric acid, 200 μl of tartrate solution, and 200 μl diaz-
otized Fast Garnet GBC was prepared. To stain for TRAP
activity, cells were rinsed once with PBS before adding
3.7% paraformaldehyde for 5 min at RT. The cells were then
rinsed once with deionized water, and staining solution was
added for 1 h at 37 °C. After incubation, cells were rinsed
again with deionized water, and TRAP-positive multinucleat-
ed osteoclasts were observed and photographed using a light
microscope (Leica, Germany). TRAP enzymatic activity in
the cultured medium was analyzed with a microplate reader
(Synergy HTX multi-mode Reader, BioTek, Winooski, VT,
USA) at 405 nm.
RNA extraction and real-time qPCR
RNA from cultured cells was isolated using the RNeasy Mini
Kit (Qiagen) according to the manufacturer’s instructions.
Briefly, cells were washed with PBS and then lysed with 2-
mercaptoethanol (Sigma-Aldrich, St. Louis, USA). The cell
extract was collected, mixed with 70% ethanol before isolat-
ing RNA using a RNeasy column. Subsequently, the obtained
RNA was dissolved in RNase-free water, and the RNA con-
centration was measured with a spectrophotometer
(NanoDrop 2000, Thermo Scientific, Wilmington, DE,
Fig. 1 Sequence of events in periodontal l igament cells/
lipopolysaccharide (LPS/PDLC)-induced osteoclastic differentiation of
RAW264.7. 1. LPS-stimulated PDLCs select and attract osteoclast pre-
cursors (e.g., RAW264.7). 2. Following adhesion of RAW246.7 cells,
PDLCs increase the expression of osteoclast promoting signaling mole-
cules, such as RANKL, M-CSF, and TNFα. 3. PDLCs retract leading to
the maturation and migration of RAW246.7 to the bone surface. The
following sequence of events and illustration is modified from Sokos
et al. [5]. Receptor activator of nuclear factor-κB (RANKL), macrophage
colony-stimulating factor (M-CSF), tumor necrosis factor-alpha (TNFα)
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USA). RNA was used to reverse transcribe first-strand cDNA
using the iScriptTM Select cDNA Synthesis Kit (Bio-Rad,
CA, USA). Thereafter, cDNA was further amplified, and the
expression of specific genes was quantified using quantitative
polymerase chain reaction (qPCR) MasterMix Plus for
SYBR® Green I (Eurogentec, Seraing, Belgium) and a real-
time PCR detection system (CFX96TM Real-Time PCR
Detec t ion Sys tem, Bio -Rad) . Os teoc la s togen ic
differentiation-related marker genes were evaluated, including
tartrate-resistant acid phosphatase (TRAP), receptor activator
of nuclear factor kappa-B ligand (RANKL), cathepsin k (CK).
The sequence of applied primers is given in Table 2. The
expression levels were analyzed and normalized with the
house-keeping gene glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) by calculating ΔCt (Ctgene of interest -
CtGAPDH), and the expression of the tested gene was calculat-
ed using the 2−(ΔCt).
Statistical analysis
Statistical differences were evaluated using one-way analysis
of variance (ANOVA) test with a pairwise multiple-
comparison test (Tukey test) to assess significant difference
in TRAP enzymatic activity, resorption pit formation, and
gene expression between groups. All statistical analysis was
performed using the GraphPad Prism v.5 (GraphPad
Software, San Diego, USA). Data are expressed as mean ±
standard deviation (SD). Differences were statistically signif-
icant when p < 0.05. For all assays, three independent exper-
iments were performed using different cell batches, in which
the experimental specimens were present in triplicate (n = 3).
Results
Characterization of calcium coating
SEM micrographs of the CaP-coated glass slides (Fig. 2a)
showed a homogeneous and uniform distribution, with a coat-
ing thickness of ~ 5 μm as detected by a Universal Surface
Tester (Fig. 2e). The XRD patterns (Fig. 2c) displayed diffrac-
tion lines characteristic of hydroxyapatite (HA), which were
comparable with literature [26]. Moreover, FT-IR spectra
(Fig. 2d) of the CaP coating revealed characteristic bands at
1032, 605, and 565 cm−1, which are attributed to the phos-
phate groups (PO4
3) in the HA chemical structure [28]. Also,
the SEM micrographs revealed that treatment of RAW264.7
cells in just basic medium did not affect the HA coating and
left the coating intact (Fig. 2b I and II), while the sheer size
and number of osteoclasts (± 50−100 μm) were strongly up-
regulated upon treatment of RAW246.7 cells with differenti-
ation medium (basic medium supplemented with RANKL)
for up to 5 days (Fig. 2B III and IV).
Osteoclast resorption
Microscopic images showed an intact coating in re-
sponse to cells cultured with medium alone (control)
(Fig. 3aI). However, several resorption pits were found
on the CaP coating following incubation of osteoclasts
with RANKL or with LPS/PDLC stimulation (Fig. 3a II
and VI). For both types of stimulation of the RAW
cells, the relative area of osteoclasts was visually down-
regulated in response to LXA4 treatment (Fig. 3a III
and VII). Conversely, the inhibitory effect of LXA4
was visibly reversed upon treatment with LXA4 togeth-
er with its receptor inhibitor, Boc-2 (Fig. 3b IV and
VIII).
Furthermore, the total resorbed area (%) relative to the
control (medium alone) in response to the indicated condition
was measured (Fig. 3b I and II). In agreement with the visual
inspection, quantitative analysis revealed no significant
changes in resorption activity of the RAW cells supplemented
with control medium. However, a significant increase in the
resorptive capacity was observed in response to either
RANKL or the LPS/PDLC challenge alone compared with
control (p < 0.001 and p < 0.01, respectively). Furthermore,
a significant decrease in osteoclastic resorptive activity was
measured in response to treatment of both groups with LXA4
compared with RANKL or LPS/PDLC-treatment (p < 0.001
and p < 0.01, respectively). Conversely, a significant increase
in osteoclast resorption activity was observed upon treatment
of RANKL or LPS/PDLC-challenged cells with LXA4 and
Boc-2, as compared with LXA4 treatment alone (p < 0.001
and < 0.05, respectively).
Table 2 List of primers (sequence 5′ to 3′, sense and antisense).




GAPDH TGA CCA CAG TCC ATG CCA TC GAC GGA CAC ATT GGG GGTA G
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TRAP staining and TRAP enzymatic activity assay
TRAP staining was used as a marker of osteoclastic differen-
tiation, and visual inspection showed that the number of mul-
tinucleated TRAP-positive cells was markedly upregulated in
response to stimulation with RANKL or LPS/PDLC (Fig. 4a
II and VI, respectively). Characteristically, RANKL-derived
osteoclasts were noticeably larger compared with LPS/PDLC-
derived osteoclasts. Nevertheless, treatment of RANKL or
LPS/PDLC-stimulated osteoclasts with LXA4 significantly
downregulated the size and number of osteoclasts (Fig. 4a
III and VII). Conversely, treatment with LXA4 along with
Boc-2 significantly reversed the inhibitory activity of LXA4
(Fig. 4a IV and VIII).
Furthermore, TRAP activity in cell culture media was also
measured to confirm the visual inspections (Fig. 4b). In
agreement with morphological assessment, a significant
increase in TRAP activity was observed following treatment
of RAW264.7 cells with RANKL or LPS/PDLC (p < 0.0001
and p < 0.001, respectively). Moreover, TRAP activity was
significantly decreased back to baseline level upon treatment
of RANKL as well as LPS/PDLC-stimulated cells with LXA4
alone (p < 0.05 and p < 0.001, respectively). Conversely, the
inhibitory activity of LXA4 was suppressed by treatment with
Boc-2, and TRAP activity was once again significantly differ-
ent compared with the control (p < 0.05 and p < 0.001, respec-
tively). No dose-dependent inhibition was observed, as all the
LXA4 concentrations investigated strongly inhibited RANKL
as well as PDLCs/LPS-induced osteoclastic differentiation
(Fig. 4d).
Real-time PCR
Finally, the expression of osteoclast-specific genes was ana-
lyzed to investigate the underlying mechanism by which
LXA4 induces the inhibition of RANKL and LPS/PDLC-
stimulated osteoclastogenesis. RANKL stimulation signifi-
c a n t l y u p r e g u l a t e d t h e e x p r e s s i o n l e v e l o f
Fig. 2 Scanning electron microscopy of (a) (I and II) calcium phosphate
(CaP) coated glass, and (III and IV) pristine glass as reference.
Magnification: × 1000 and × 10,000. Scale bar: 10 μM. (b) (I and II)
SEM microscopy of RAW246.7 cultured on CaP-coated glass slides cul-
tured with treated with basic medium, or (III and IV) RAW cells cultured
in differentiation medium (RANKL) for up to 5 days. Magnification ×
1000 and × 5000. Scale bar: 10 μm. Arrows indicate resorption of CaP
substrate; asterisks (*) indicate presence of osteoclasts. (c) X-ray diffrac-
tion (XRD) patterns of the calcium coating on a glass slide. Crosses “×”
indicate hydroxyapatite peaks (d) FT-IR spectra of (a) CaP glass slide, (b)
α-TCP, and (c) pristine glass. Dashed lines indicate phosphate bands. (e)
Surface characterization of CaP substrate displaying a coating thickness
of ~ 5 μm
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osteoclastogenesis-associated gene expression (RANKL,
TRAP, and CK mRNA) in RAW264.7 in monoculture (Fig.
5a–c). Similarly, LPS/PDLC stimulation significantly upreg-
ulated the expression levels of osteoclast-specific genes rela-
tive to the control (Fig. 5d–f). Accordingly, the expression
level of osteoclast genes was markedly higher in response to
RANKL treatment compared with LPS/PDLC stimulation.
Overall, the treatment of cells with LXA4 significantly down-
regulated the expression level of osteoclastogenesis marker
genes in either case. Lastly, treatment of both types of stimu-
lated cells with Boc-2 reversed the inhibitory effect of LXA4
back to baseline.
Discussion
Previous investigations into the pathogenesis of periodontal dis-
ease have typically centered on the role of bacterial infection.
However, over the past decade, there has been an increasing
interest in the inflammatory response that occurs after infection
and which gives rise to osteoclastic bone resorption [29]. In view
of this, it has been demonstrated that PDLCs, although not com-
monly regarded as inflammatory cells, might also play a role and
are contributing to the differentiation of osteoclasts by their in-
teraction with osteoclast progenitor cells [30–32]. In periodontal
disease, bacterial colonization alters the phenotype of PDLCs by
activating inflammatory signaling pathways, which promote
tissue-destructive responses [7, 33]. Subsequently, osteoclastic
differentiation is promoted by cell-cell-mediated interactions be-
tween PDLCs and OPCs—a phenomenon facilitated by adhe-
sion molecules (e.g., ICAM) and release of inflammatory factors
(i.e., cytokines, chemokines) [29, 34, 35]. Cell-cell crosstalk be-
tween PDLCs and OPCs leads to the migration of TRAP-
positive OPCs to the bone surface where osteoclastogenesis oc-
curs, resulting in bone resorption [29, 34, 35]. In the current
study, we aimed to set up a similar model, yet in an in vitro
environment, to test novel types of medication, which can aid
in the treatment of periodontitis. Therefore, a coculture system
Fig. 3 (a) Images of calcium phosphate (CaP)-coated glass substrates
after staining with silver nitrate (AgNO3) following incubation with (I)
basic medium (control), (II) RANKL (alone, 50 ng/ml), (III) RANKL+
LXA4 (50 ng/ml), (IV) RANKL+LXA4+Boc-2 (10 μM), or in RAW/
PDLC coculture in medium supplemented with (V) basic medium (con-
trol), (VI) LPS (alone, 10 μg/ml), and (VII) LPS+LXA4 (50 ng/ml),
(VIII) LPS+LXA4+Boc-2 (10 μM). Resorbed pits are shown in white,
and intact CaP coating is stained black. Note that LXA4 inhibits RANKL
or LPS/PDLC-induced osteoclast resorption of CaP coating, and Boc-2
reversed this effect. Magnification: × 10,000. Scale bar: 200 μm. (b)
Quantification of resorption pit area (%) resorbed by osteoclasts obtained
following incubation of RAW264.7 with (I) RANKL (alone), and (II)
LPS (alone) under the same conditions. Statistical analysis was performed
by one-wayANOVAwith Tukey post-test, n = 100 *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001. Asterisks on top of the columns indicate significant differ-
ences from the control
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was set up, closely mimicking the in vivo situation described
above.
The periodontal microenvironment contains a wide diver-
sity of oral pathogens which play an important role in peri-
odontal health or disease. The periodontal biofilm is heterog-
enous with approximately 7000 organisms [36, 37]. Although
oral pathogenic bacteria, such as P. gingivalis, are commonly
associated with PD, “non-oral” pathogens (e.g., E. coli) have
also recently been implicated in the pathogenesis of this dis-
ease [38]. Several studies reported on the presence of non-oral
bacterial species after microbiological analysis of the
subgingival biofilm of PD patients [39, 40]. Analysis of the
subgingival biofilm samples from a large number of untreated
chronic PD patients revealed elevated levels of E. coli com-
pared with non-PD subjects [39]. Souto and co-workers re-
vealed a positive correlation with clinical signs of PD with
bacterial pathogens, including E. coli, Staphylococcus aureus,
and Pseudomonas aeruginosa [40]. In primary PDLCs, an
inflammatory phenotype was induced by adding bacterial
E. coli LPS, which in term should trigger osteoclast formation
by inducing RANKL expression in osteoblasts and other stim-
ulatory factors (IL-1, prostaglandins, TNFα) leading up to
bone resorption [41]. While oral pathogens are more patho-
logically relevant bacterial source, E. coli-derived LPS is more
effective at inducing bone resorption in vitro because it is a
strong inflammatory agonist for toll-like receptors (TLRs)
[42–44] [45]. Conversely, P. gingivalis LPS induces a signif-
icantly lower expression of inflammatory cytokines (e.g., IL-
6) compared with E. coli LPS [46]. Considering PDLCs pro-
duce a little inflammatory profile, E. coli LPS is commonly
used to trigger an inflammatory immune response [47]. The
subgingival biofilm of PD patients is complex with higher
proportion of periodontal pathogens, including lesser known
ones, and knowing the effect of different microorganisms is
fundamental to our understanding of the complexmechanisms
involved in this multifactorial disease.
Fig. 4 (a) Tartrate-resistant acid phosphatase (TRAP) staining in
RAW264.7 cells in monoculture (I–IV) treated with (I) basic medium
(control), (II) RANKL (alone, 50 ng/ml), (III) RANKL + LXA4 50
ng/ml, (IV) RANKL+LXA+Boc-2. TRAP staining in RAW264.7 cells
in coculture with PDLCs (V–VIII) treated with (V) basic medium (con-
trol), (VI) LPS (alone,10 μg/ml), (VII) LPS + LXA4 (50 ng/ml), and
(VIII) LPS+LXA+Boc-2 (10 μM). Note that LXA4 inhibits RANKL
and LPS/PDLC-induced osteoclastic differentiation, while Boc-2 re-
versed this response. Magnification: × 20,000. Scale bar: 100 μm. (b–
d) TRAP enzymatic activity in the culture medium obtained from (b)
RAW264.7 cells in monoculture, and (c) RAW264.7 cells in coculture
with PDLCs. Note that LXA4 inhibited RANKL, and LPS/PDLC in-
creased TRAP activity. (d) Effect of increasing concentration of LXA4
(62.5, 125, and 250 ng/ml) in LPS (50 ng/ml)-stimulated RAW264.7 cells
in coculture with PDLCs. Note that all concentrations of LXA4 signifi-
cantly inhibited TRAP activity. Statistical analysis was performed by
one-way ANOVA with Tukey post-test, n = 100 *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001. Asterisks on top of the columns indicate significant differ-
ences from the control
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The mechanism of LPS-induced osteoclastogenesis can be
explained as follows. Under inflammatory conditions, LPS-
stimulated PDLCs select and attract osteoclast precursors to
fuse into osteoclasts by upregulating the expression of
osteoclastogenesis-stimulating molecules [5]. During this in-
teraction, LPS binds to TLR4 receptors on PDLCs and stim-
ulates the expression of pro-inflammatory mediators, TNFα,
IL-1, and PGE2, which play a crucial role in maturation of
OPCs and bone resorption [47]. It is important to note that
LPS does not promote osteoclast differentiation in the absence
of osteoblasts/stromal cells (e.g., PDLCs) [48–50]. Thus,
LPS-promoted osteoclastogenesis can be attributed to the di-
rect cell-cell interaction between PDLCs and RAW cells and
not from direct interaction of LPS [9, 13]. As a control for our
coculture, we also stimulated osteoclast formation artificially,
as is commonly done in literature, by the addition of RANKL.
The similar results between RANKL stimulation, vs. the ef-
fects obtained by LPS/PDLC stimulation, indeedmake it plau-
sible that the LPS/PDLC route is a valid representation of the
actual situation. Moreover, the subsequent experiments with
the CaP coating proved that the RAW cells upon such stimu-
lation became actively matrix-degrading osteoclasts.
After setting up and validating the coculture system
with the clinical situation, a suitable drug strategy was
selected, for which we focused on the use of SPMs.
Among the SPMs released during inflammation, LXs are
key to the resolution of inflammation [15, 51]. LXA4
evokes several important protective responses in vivo, in-
cluding inhibition of neutrophil recruitment, activation,
and chemotaxis, via inhibition of several downstream path-
ways, such as NF-κB, and activator protein-1 (AP-1) [17,
52–57] . Moreover , LXA4 exer t s a poten t an t i -
inflammatory action by modulating leukocyte activity and
promoting phagocytosis of apoptotic cells [58]. The bind-
ing of LXA4 to its receptor (FPR2/ALXR) interferes with
osteoclastogenesis by suppressing the expression of in-
flammatory mediators (e.g., IL-1β and IL-6) via inhibition
of multiple signaling pathways, including receptor activa-
tor of nuclear factor-κB (NF-κB) [59]. Inhibition of NF-κB
suppresses the expression of pro-inflammatory cytokines,
which counteracts inflammation-induced bone resorption
[60]. The role of LXA4 in inhibition and function of oste-
oclasts has been recently described in the literature [17].
However, the role of LXA4 as a modulator of cell-cell-
mediated osteoclastogenesis remains elusive [61]. Given
the lack of studies regarding the role of LXA4 in cell-
cell-mediated osteoclast differentiation and function and
considering the importance of PDLCs in inflammation-
induced osteoclastogenesis, we investigated the effect of
LXA4 on osteoclastogenesis promoted by LPS/PDLC
Fig. 5 Expression levels of RANKL, TRAP, and CKwere determined by
qRT-PCR in (a–c) RANKL-stimulated RAW264.7 monoculture, and (d–
f) LPS/PDLC-stimulated RAW264.7. Note that LXA4 inhibited RANKL
and LPS/PDLC-induced expression of osteoclast marker genes, while
Boc-2 reversed this response. Expression levels were calculated in
relation to internal controls (GAPDH mRNA) with a comparative Ct
method. Statistical analysis was performed by one-way ANOVA with
Tukey post-test, n = 100 *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
Asterisks on top of the columns indicate significant differences from the
control
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challenge, as model system. It was hypothesized that (1)
LXA4 would inhibit osteoclast differentiation, and (2) this
effect could be reversed by the receptor antagonist, Boc-2.
Our data confirmed that both of these hypotheses were
tested true.
In the experiments, osteoclastogenesis was analyzed using
several complimentary morphological, molecular, and func-
tional assays designed to test all aspects of osteoclast forma-
tion, activity, and function. Finally, we performed RT-PCR to
fully investigate the mechanism underlying the inhibition of
osteoclastogenesis. The results from these studies indicated
that RANKL stimulation causes an upregulation in osteoclast
differentiation from OPCs. Additionally, osteoclast formation
was upregulated during cell-cell contact between PDL and
RAW cells when conditioned medium containing bacterial
LPS was used. The in vitro experiments demonstrated that
PDLCs adapt to bacterial stimuli by upregulating the expres-
sion of osteoclastogenesis-stimulating genes, resulting in the
release of pro-inflammatory mediators (i.e., cytokines and
chemokines) that enhance osteoclast activity and function.
Comparison of our results with literature corroborates with
most of these effects. For instance, Kanzaki et al. (2001)
showed that PDLCs cocultured with peripheral blood monoc-
ular cells (PMBCs) exhibited significantly more resorption
pits than PMBCs cultured alone [62]. Furthermore, Bloemen
et al. (2010) and Burger & Dayer (2002) showed direct that
cell-cell contact increased synergistically the expression of
osteoclastogenesis genes in vitro [9, 63]. Similar effects were
further demonstrated in vivo by Kim et al. (2005), who report-
ed about the formation of osteoclasts, independent of RANKL
signaling pathway, in response to stimulation with inflamma-
tory mediators (TNFα and IL-1β) [64]. Considering our re-
sults in comparison with the available literature justifies the
conclusion that PDLCs contribute to enhanced osteoclast for-
mation in periodontal disease. Evidently, PDLCs can play an
important role as a drug target when aiming to maintain he-
mostasis in the periodontium [5].
Furthermore, the results of the current study showed inhi-
bition osteoclastogenesis in response to inclusion of LXA4 in
the differentiation medium. The reduction of osteoclast for-
mation implied a strong protective role of SPMs against
inflammation-induced bone resorption, especially as it could
be reversed by the addition of a specific inhibitor. Not only the
number but also the function of osteoclasts could effectively
be modulated; i.e., the decrease in osteoclastogenesis-
associated genes was correlated with absence of resorption
pits on the CaP-coated substrates. Apparently, LXA4 carries
anti-inflammatory capacity after an in vitro encounter with
bacterial LPS. In agreement with our data, Liu et al. (2017)
showed that LXA4 treatment reduced osteoclast formation in
RANKL-stimulated RAW cells [17]. Combination of our data
and the literature information confirms again that that both our
initial hypotheses were true.
The study has potential limitations. TRAP activity, func-
tion, and osteoclast-specific gene expression was notably low-
er for LPS/PDLC compared with RANKL-stimulated RAW
cells. There are several explanations for this effect. Firstly,
LPS may negatively affect osteoclast formation by promoting
the expression of pro-inflammatory mediators (TNFα and ni-
tric oxide), which may negatively affect cell viability (even at
low concentrations) [65–67]. Secondly, RANKL is a strong
inducer of osteoclast formation [68, 69], while LPS induces
formation of osteoclasts independent of the RANKL pathway
by activating pattern recognition receptors, such as TLR4,
which can affect activation and survival of osteoclasts [5,
70]. Still, the RANKL stimulation should be considered as
an artificial control, whereas the PDLCs route might be more
physiologically relevant. Furthermore, murine RAW264.7
monocytes were integrated into the cell culture system be-
cause there is currently a lack of a reliable osteoclast model
using a human cell line [71]. While the human monocytic
leukemia cell line (THP-1) would have presented a more clin-
ically relevant model, these cells are unable to consistently
develop into multinucleated osteoclasts and are also far less
responsive to LPS [72, 73]. Therefore, it can be challenging to
extrapolate the data obtained using this human cell line. On
the contrary, murine RAW264.7 cells produce a more robust
inflammatory response when challenged with bacterial LPS
and have been extensively used to carry out in vitro screens for
immunomodulators [74].
Conclusion
In conclusion, our findings demonstrate the importance
of cell-cell signaling between PDLCs and osteoclast pre-
cursors in inflammation-induced osteoclastic differentia-
tion. In addition, our data validate the inhibitory role of
LXA4 in this process. It is important to note that the
current data are the result of in vitro study and might
not reflect the clinical in vivo situation. Hence, in vivo
(pre)clinical experiments are needed to fully validate
whether LXA4 can indeed inhibit osteoclastogenesis
and prevent inflammation-induced bone resorption.
Nevertheless, the results merit such further investigation
and provide important considerations for the implemen-
tation of LXA4 in periodontal therapy.
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